-
Xianglei Tangzu Cream Approved with Conditions for Marketing
2023-11-14
Recently, the natural products Category 1.1 innovative drug Xianglei Tangzu Cream (Fespixon Cream) of Oneness Biotech Co., Ltd. was approved for marketing with conditions by China NMPA.
-
Glofitamab Injection Approved with Conditions for Marketing
2023-11-08
Recently, the Glofitamab Injection (trade name: 高罗华/Columvi) of Roche Pharma (Schweiz) AG is approved with conditions by China NMPA.
-
Aponermin for Injection Approved for Marketing by China NMPA
2023-11-02
Recently, the Aponermin for Injection (Chinese trade name:沙艾特) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved by China NMPA.
-
Children's Zibei Xuanfei Syrup Approved for Marketing
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Children's Zibei Xuanfei Syrup of Jianmin Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
-
Tongluo Mingmu Capsules Approved for Marketing by China NMPA
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Tongluo Mingmu Capsules of Shijiazhuang Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Ritlecitinib Tosylate Capsules Approved for Marketing
2023-10-19
Recently, the Category 1 innovative drug Ritlecitinib Tosylate Capsules (trade name: LITFULO ®) of Pfizer Inc. is approved for marketing through priority review and approval procedures by China NMPA.
